166 related articles for article (PubMed ID: 32945554)
21. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
22. High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
Nomura Y; Karube K; Suzuki R; Ying G; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Cancer Sci; 2008 Feb; 99(2):246-52. PubMed ID: 18271922
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
[TBL] [Abstract][Full Text] [Related]
24. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.
Braziel RM; Arber DA; Slovak ML; Gulley ML; Spier C; Kjeldsberg C; Unger J; Miller TP; Tubbs R; Leith C; Fisher RI; Grogan TM
Blood; 2001 Jun; 97(12):3713-20. PubMed ID: 11389007
[TBL] [Abstract][Full Text] [Related]
25. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
26. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.
Thomas N; Dreval K; Gerhard DS; Hilton LK; Abramson JS; Ambinder RF; Barta S; Bartlett NL; Bethony J; Bhatia K; Bowen J; Bryan AC; Cesarman E; Casper C; Chadburn A; Cruz M; Dittmer DP; Dyer MA; Farinha P; Gastier-Foster JM; Gerrie AS; Grande BM; Greiner T; Griner NB; Gross TG; Harris NL; Irvin JD; Jaffe ES; Henry D; Huppi R; Leal FE; Lee MS; Martin JP; Martin MR; Mbulaiteye SM; Mitsuyasu R; Morris V; Mullighan CG; Mungall AJ; Mungall K; Mutyaba I; Nokta M; Namirembe C; Noy A; Ogwang MD; Omoding A; Orem J; Ott G; Petrello H; Pittaluga S; Phelan JD; Ramos JC; Ratner L; Reynolds SJ; Rubinstein PG; Sissolak G; Slack G; Soudi S; Swerdlow SH; Traverse-Glehen A; Wilson WH; Wong J; Yarchoan R; ZenKlusen JC; Marra MA; Staudt LM; Scott DW; Morin RD
Blood; 2023 Feb; 141(8):904-916. PubMed ID: 36201743
[TBL] [Abstract][Full Text] [Related]
27. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.
Pillon M; Mussolin L; Carraro E; Conter V; Aricò M; Vinti L; Garaventa A; Piglione M; Buffardi S; Sala A; Santoro N; Lo Nigro L; Mura R; Tondo A; Casale F; Farruggia P; Pierani P; Cesaro S; d'Amore ES; Basso G
Br J Haematol; 2016 Nov; 175(3):467-475. PubMed ID: 27392319
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
29. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.
Soldini D; Montagna C; Schüffler P; Martin V; Georgis A; Thiesler T; Curioni-Fontecedro A; Went P; Bosshard G; Dehler S; Mazzuchelli L; Tinguely M
Ann Oncol; 2013 Jan; 24(1):193-201. PubMed ID: 22967991
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.
Qin C; Huang Y; Feng Y; Li M; Guo N; Rao H
Diagn Pathol; 2018 Feb; 13(1):17. PubMed ID: 29482573
[TBL] [Abstract][Full Text] [Related]
31. Diffuse large B-cell lymphomas and burkitt lymphoma.
de Leval L; Hasserjian RP
Hematol Oncol Clin North Am; 2009 Aug; 23(4):791-827. PubMed ID: 19577170
[TBL] [Abstract][Full Text] [Related]
32. Reappraisal of Primary Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract: Comparative Analysis Among Immunosuppressed and Nonimmunosuppressed Stage I and II-IV Patients.
Miyagi S; Ishikawa E; Nakamura M; Shimada K; Yamamura T; Furukawa K; Tanaka T; Mabuchi S; Tsuyuki Y; Kohno K; Sakakibara A; Satou A; Kato S; Fujishiro M; Nakamura S
Am J Surg Pathol; 2020 Sep; 44(9):1173-1183. PubMed ID: 32349049
[TBL] [Abstract][Full Text] [Related]
33. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
34. Histological characteristics of 21 Papua New Guinean children with high-grade B-cell lymphoma, which is frequently associated with EBV infection.
Nomura Y; Lavu EK; Muta K; Niino D; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
Pathol Int; 2008 Nov; 58(11):695-700. PubMed ID: 18844934
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
Kaji D; Kusakabe M; Sakata-Yanagimoto M; Makishima K; Suehara Y; Hattori K; Ota Y; Mitsuki T; Yuasa M; Kageyama K; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto H; Asano-Mori Y; Ubara Y; Izutsu K; Uchida N; Wake A; Taniguchi S; Yamamoto G; Chiba S
Br J Haematol; 2021 Nov; 195(4):585-594. PubMed ID: 34558064
[TBL] [Abstract][Full Text] [Related]
36. Epstein barr virus IgG and EBER-1 in Burkitt's lymphoma children at a referral hospital in western Kenya.
Ndede I; Mining SK; Patel K; Wanjala FM; Tenge CN
Pan Afr Med J; 2019; 34():206. PubMed ID: 32180880
[TBL] [Abstract][Full Text] [Related]
37. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus (EBV) provides survival factors to EBV
Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
[TBL] [Abstract][Full Text] [Related]
40. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
